Welcome to our dedicated page for OSMT news (Ticker: OSMT), a resource for investors and traders seeking the latest updates and insights on OSMT stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect OSMT's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of OSMT's position in the market.
RVL Pharmaceuticals plc (formerly Osmotica Pharmaceuticals plc) announced significant growth in UPNEEQ sales, achieving approximately $3.1 million in Q4 2021, a 41% increase from Q3 2021. The company targets net sales for Q4 2022 to reach between $20 million and $25 million, as it prepares for a full national launch into medical aesthetics in February 2022. RVL emphasizes its unique business model to enhance the marketing of UPNEEQ, the first FDA-approved treatment for acquired blepharoptosis, further establishing its presence in both eye care and aesthetics.
Osmotica Pharmaceuticals has rebranded to RVL Pharmaceuticals as part of its strategy to expand into eye care and medical aesthetics. The company reported that UPNEEQ net sales grew by 41% in Q4 2021, reaching $3.1 million, and projected Q4 2022 sales between $20 million and $25 million. A full national launch into medical aesthetics is expected in February 2022. The company increased unique pharmacy prescribers by 30% to 10,500 by year-end 2021, indicating strong market penetration and growth potential.
Osmotica Pharmaceuticals plc (NASDAQ: OSMT) announced a video webcast on January 19, 2022, hosted by CEO Brian Markison and COO James Schaub. They will share insights on UPNEEQ® trends, the company's expansion plans into the medical aesthetics market, and other business updates. Featured speakers include Dr. Jackie Yee, a specialist in Aesthetic Injectables, and Dr. Justin Harper, an Aesthetic Physician. The webcast begins at 8:30 a.m. ET and will be available later on the company's website.
Osmotica is known for UPNEEQ®, the first FDA-approved non-surgical treatment for acquired blepharoptosis.
Osmotica Pharmaceuticals (Nasdaq: OSMT) announced a conference call on January 19, 2022, at 8:30 a.m. ET. Key executives, including CEO Brian Markison and COO JD Schaub, will discuss UPNEEQ® trends, plans for entering the medical aesthetics market, and other business updates. Shareholders can access the live webcast here. The event will also be available for replay on the company’s website under the “Investor & News” section.
Osmotica Pharmaceuticals (Nasdaq: OSMT) announced that CEO Brian Markison, COO James Schaub, and CFO Andrew Einhorn will present at the H.C. Wainwright Bioconnect Conference on January 10, 2022, at 7:00 AM ET. The presentation will be available for on-demand viewing for 30 days via the provided webcast link and the Company’s website. Osmotica focuses on developing pharmaceutical products for underserved markets, with additional operations in Hungary.
Osmotica Pharmaceuticals reported third-quarter 2021 results with Upneeq product sales reaching $2.2 million, a 47% increase from the second quarter. The company launched its Direct Dispense program, engaging over 400 eyecare practices. Despite significant growth in Upneeq sales, total revenues decreased from $25.8 million in Q3 2020 due to a prior-year regulatory milestone payment. The net loss from continuing operations was $26.3 million, outweighing a previous net income. Cash reserves stood at $8.4 million, with debt totaling $29.9 million.
Osmotica Pharmaceuticals (Nasdaq: OSMT) will present at the Jefferies London Virtual Healthcare Conference on November 18, 2021. CEO Brian Markison, COO James Schaub, and CFO Andrew Einhorn will lead the presentation at 8:00 AM GMT (3:00 AM ET). The event will be available for on-demand viewing for 30 days, accessible via the provided link or on Osmotica's website under the 'Investor & News' section. Osmotica focuses on developing products for underserved patient populations, with operations in the U.S. and Hungary.
Osmotica Pharmaceuticals plc (Nasdaq: OSMT) will announce its third quarter financial results for 2021 on November 15, 2021, after U.S. market close. A conference call will be held at 4:30 p.m. ET, featuring CEO Brian Markison, COO JD Schaub, and CFO Andrew Einhorn. Investors can join the call by dialing (866) 672-5029 for U.S. participants or (409) 217-8312 for international callers, using Conference ID 57399556. The live webcast and replay will be available on the company’s website.
On October 12, 2021, Osmotica Pharmaceuticals (Nasdaq: OSMT) completed its underwritten public offering of 14 million ordinary shares and warrants at $2.50 each, generating about $35 million in gross proceeds. The warrants, exercisable at $3.10, will expire in three and a half years. The offering included a 30-day option for underwriters to purchase an additional 2.1 million shares and warrants. H.C. Wainwright & Co. managed the offering, with the securities registered under a shelf registration statement filed with the SEC.
Osmotica Pharmaceuticals has announced a note purchase agreement for up to $100 million in senior secured notes with Athyrium Capital Management. This financing aims to support the commercialization of Upneeq, a first-in-class treatment for acquired ptosis. Upon closing, Osmotica is set to issue $55 million in notes, with potential additional notes based on revenue targets. The notes mature in October 2026. The partnership with Athyrium is expected to bolster Osmotica's growth initiatives in the healthcare sector.
